Kelonia Therapeutics Inc.

Plus: CMO Maria Koehler steps down at Repare, and updates from Isomab, Crescent, Ottimo and Senti Bio

Across disciplines, researchers are navigating trade-offs in advancing translation that boil down to scope versus focus 

Plus: Daniel Janse named CEO at AffyImmune, and updates from HanAll, Mogrify, Rectify and Atsena

Plus: Xoma-Kinnate, Almirall-Novo, Intellia-ReCode, Roche-Repare and more

Off switches and non-viral delivery technologies may be the solution to CAR Ts’ most recent safety problem

Kelonia shows safety in non-human primates, while Umoja shows efficacy in solid tumors in mice

Four axes of risk map how companies founded in the last five years are innovating in CAR T and TCR T cells

A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology

Plus CRISPR’s Klein steps down, and updates from Acadia, 10 Downing Street and Venrock

Capstan debuts with a Pfizer Ventures-led $102M series A, Penn technology to create in vivo cell therapies